Comparison of Insulin Detemir Produced by the Current Process and the NN729 Process in Healthy Subjects

Phase 1 Completed 37 enrolled Novo Nordisk A/S

RandomizedCrossoverDouble-blindTreatment

Summary

This trial is conducted in Europe. The aim of this trial is to demonstrate bioequivalence between insulin detemir produced by the NN729 process and by the current process in healthy subjects.

Timeline

Start: 2006-08
Primary completion: 2006-11
Completion: 2006-11

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	insulin detemir	Protein / enzyme biologic	—	Subcutaneous

Comparison of Insulin Detemir Produced by the Current Process and the NN729 Process in Healthy Subjects

Summary

Timeline

Drugs

Indications